Krystal Biotech, Inc. 8-K

What Happened
Krystal Biotech, Inc. (KRYS) filed an 8‑K on February 17, 2026 under Item 2.02 to announce its financial results for the quarter and fiscal year ended December 31, 2025. The company attached a press release summarizing those results as Exhibit 99.1. The filing was signed by Chairman and CEO Krish S. Krishnan.

Key Details

• Filing date: February 17, 2026 (Form 8‑K, Item 2.02).
• Reporting period: Quarter and year ended December 31, 2025.
• Exhibit: Press release with results attached as Exhibit 99.1 (also includes Inline XBRL cover page, Exhibit 104).
• Legal note: The earnings information in the 8‑K and Exhibit 99.1 is furnished (not “filed”) and is not subject to Section 18 liability or automatically incorporated into future SEC registration statements.

Why It Matters
This filing signals Krystal has publicized its latest quarterly and annual earnings information — a material update for investors tracking revenue, profitability, guidance, or program milestones. Because the 8‑K attaches a press release rather than embedding detailed financials in the body of the filing, investors should review Exhibit 99.1 and the company’s upcoming 10‑K/quarterly filings or earnings call for full figures and context. The legal disclaimer means the press release is furnished to the SEC (informational) rather than “filed” for certain regulatory liability and incorporation purposes.